Neurological Biomarkers Market Size, Share & Trends Report

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism Spectrum Disorder), By Type, By End-use, By Region, And Segment Forecasts, 2019 - 2026

  • Published Date: Oct, 2019
  • Base Year for Estimate: 2018
  • Report ID: GVR-3-68038-823-7
  • Format: Electronic (PDF)
  • Historical Data: 2015 - 2017
  • Number of Pages: 100

Industry Insights

The global neurological biomarkers market size was estimated at USD 5,564.8 million in 2018 and is expected to exhibit a CAGR of 14.5% during the forecast period. Rising prevalence of neurological diseases and increasing emphasis on early diagnosis & treatment are expected to drive the market growth.

High prevalence of neurological disorders is a key driver for this market. As per the WHO estimates published in 2018, over 300 million people of all ages suffer from clinical depression, worldwide. Furthermore, lack of efficient diagnostics in developing and undeveloped countries may enhance the mortality rate of neurological disorders. For instance, according to École des Neurosciences de Paris Île-de-France (ENP), more than 6 million people die due to stroke each year, out of which - nearly 80% belong to middle- and low-income countries.

U.S. neurological biomarkers market

There are more than 600 types of neuro-disorders affecting the brain, spine, or nerves. Although some prevalent disorders such as cerebral stroke, Alzheimer’s disease, Parkinson’s disease, brain tumors, and epilepsy, are well-studied, most neurological disorders are complicated and rare requiring further in-depth knowledge about the underlining pathophysiology.

Proactive government initiatives and increasing funding for neurological diagnostics are expected to drive higher growth in this market. For instance, the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health - NIH, is focused on reducing the global burden of neurological diseases by enforcing regulatory strategies, evaluating diagnostic & therapeutic approaches in neurology, and creating job opportunities for neuroscience research.

Application Insights

Alzheimer’s disease is the leading application of neurological biomarkers, recording the highest prevalence among sexagenarians and older people. Amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau) are some of the key cerebrospinal fluid biomarkers reflecting the pathophysiology of this condition. Identification of these biomarkers in the early stages of the disease can help in timely treatment.

There are ground-breaking research trials ongoing for improved diagnostics of Parkinson’s disease. Earlier, protein biomarkers, amino acids, and dopamine metabolites were the prime analytical tools for diagnosing Parkinson’s disease. However, several novel candidates are under investigation for potential diagnostic biomarkers.

Type Insights

Genomic neurological biomarkers accounted for the largest share in 2018, driven by rising consumer awareness and technological advancements. The segment growth is also supported by the shifting diagnostic paradigm towards gene analysis and genetic counselling. Genomic biomarkers can direct the future of neurological practice towards a more personalized approach based on the patient’s individual genetic specifications and predispositions.

Imaging biomarkers are positioned to reflect the highest growth rate through the forecast years, fueled by extensive R&D in neuroscience and technological advancements that have enabled visualization of abnormalities within the body. Furthermore, proteomic and metabolomic biomarkers are expected to witness modest growth in the near future.

End-use Insights

Hospital laboratories dominated the end-use segment, in 2018. The growth of this segment can be attributed to increasing patient inflow for cancer diagnosis in hospitals, growing consumer awareness, and rising investments in healthcare infrastructure in developing and underdeveloped countries.

Global neurological biomarkers market

The market for research organizations is expected to grow at the highest rate during the forecast period owing to increasing funding for neuroscience research worldwide. For instance, the NINDS Human Biomarkers Biospecimen and Data Repository (BioSEND) is dedicated to the discovery and identification of neurological biomarkers.

Regional Insights

North America accounted for more than 37% market share in 2018, owing to strong commercial performances of neurological diagnostics in the U.S. Some of the other factors contributing to the growth include proactive government initiatives, increase in healthcare expenditure, and local presence of key manufacturers.

Asia Pacific is projected to observe the fastest growth throughout the forecast period. The overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely to contribute to the regional growth rate. Emerging countries, such as China, India, and South Korea, are expected to observe strong growth in the neurological biomarkers market.

Neurological Biomarkers Market Share Insights

Some key players operating in this market include Abbott; QIAGEN; Myriad RBM; Thermo Fisher Scientific Inc.; Athena Diagnostics; Bio-Rad Laboratories, Inc.; AbaStar MDx, Inc.; Acumen Pharmaceuticals; BANYAN BIOMARKERS, INC.; and Alseres Pharmaceuticals, Inc.

Major market players employ strategies such as merger & acquisitions, licensing partnerships, and co-development deals - making this market highly competitive. Key companies are focusing on new product development. For instance, in September 2017, Abbott closed its acquisition of Alere Inc. This has resulted in the addition of point-of-care division into Abbott’s business portfolio.

Report Scope



Base year for estimation


Actual estimates/Historical data

2015 - 2017

Forecast period

2019 - 2026

Market representation

Revenue in USD Million & CAGR from 2018 to 2026

Regional scope

North America, Europe, Asia Pacific, Latin America, MEA

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Country scope

U.S., Canada, U.K., Germany, France, Italy, Spain, Mexico, Brazil, Argentina, Japan, China, India, South Korea, Australia, South Africa, UAE, Saudi Arabia

15% free customization scope (equivalent to 5-analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global neurological biomarkers market on the basis of application, type, end-use, and region:

  • Application Outlook (Revenue, USD Million, 2015 - 2026)

    • Alzheimer’s Disease

    • Parkinson’s Disease

    • Multiple Sclerosis

    • Autism Spectrum Disorders

    • Others

  • Type Outlook (Revenue, USD Million, 2015 - 2026)

    • Genomic

    • Proteomic

    • Metabolomic

    • Imaging

    • Others

  • End-use Outlook (Revenue, USD Million, 2015 - 2026)

    • Hospital Laboratories

    • Independent Clinical Diagnostic Centers

    • Research Organizations

    • Others

  • Regional Outlook (Revenue, USD Million, 2015 - 2026)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • Spain

      • France

      • Italy

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Pricing & Purchase Options

Service Guarantee

  • Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Confidentiality

    We are in compliance with GDPR & CCPA norms. All interactions are confidential.

  • Custom research service

    Design an exclusive study to serve your research needs.

  • 24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities